FSCN1 and triple-negative breast carcinoma: We have shown that fascin inhibitors can inhibit the migration, invasion and metastasis of triple-negative breast cancer cells and neuroendocrine prostate cancer cells, as well as increase the overall survival of mice bearing triple-negative breast tumors or NEPC.